Elicio Therapeutics, Inc.
NASDAQ Global MarketTotal Valuation
Elicio Therapeutics, Inc. carries a market capitalization of 29.55M, placing it among publicly traded companies globally. Its enterprise value stands at 76.30M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.55M |
| Enterprise Value | 76.30M |
Share Statistics
Elicio Therapeutics, Inc. currently has 21.90M shares outstanding.
| Shares Outstanding | 21.90M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 10.79 |
| P/TBV Ratio | 10.79 |
| P/FCF Ratio | -1.87 |
| P/OCF Ratio | -1.87 |
Financial Position
Elicio Therapeutics, Inc. maintains a current ratio of 2.77, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 178.25, indicating elevated leverage, while an interest coverage ratio of -23.28 demonstrates limited ability to service its debt obligations.
| Current Ratio | 2.77 |
| Quick Ratio | 2.55 |
| Debt / Equity | 178.25 |
| Debt / EBITDA | -0.38 |
| Interest Coverage | -23.28 |
Financial Efficiency
| Return on Equity (ROE) | -774.56 |
| Return on Assets (ROA) | -124.36 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Elicio Therapeutics, Inc.'s stock has declined approximately -83.64979% over the past 52 weeks. The 50-day moving average sits at 2.30, while the 200-day moving average is 7.06.
| Beta (5Y) | N/A |
| 52-Week Price Change | -83.64979% |
| 50-Day Moving Average | 2.30 |
| 200-Day Moving Average | 7.06 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -36.78M, while operating income came in at -37.92M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -37.92M |
| Pretax Income | -37.84M |
| Net Income | -37.84M |
| EBITDA | -36.78M |
| EBIT | -37.92M |
| Earnings Per Share (EPS) | -2.10 |
Balance Sheet
Elicio Therapeutics, Inc. holds 23.48M in cash and equivalents against 14.15M in total debt, resulting in a net debt position of -13.94M. Total book value stands at 7.94M, with working capital of 16.28M providing operational flexibility.
| Cash & Cash Equivalents | 23.48M |
| Total Debt | 14.15M |
| Net Debt | -13.94M |
| Equity (Book Value) | 7.94M |
| Book Value Per Share | 0.36 |
| Working Capital | 16.28M |
Cash Flow
Elicio Therapeutics, Inc. produced -37.69M in operating cash flow over the past twelve months. After subtracting -16,000.00 in capital expenditures, free cash flow totaled -37.71M - equivalent to -2.09 per share.
| Operating Cash Flow | -37.69M |
| Capital Expenditures | -16,000.00 |
| Free Cash Flow | -37.71M |
| FCF Per Share | -2.09 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -45.51 |
| FCF Yield | -53.39 |
Stock Splits
Elicio Therapeutics, Inc.'s most recent stock split took place on June 2, 2023 with a 10:1 split ratio.
| Last Split Date | 6/2/2023 |
| Split Ratio | 10:1 |
Scores
Elicio Therapeutics, Inc. posts an Altman Z-Score of -12.51, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -12.51 |